SciSparc Ltd.SPRCEarnings & Financial Report
SciSparc Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in the neurological, psychiatric, and gastrointestinal disorder segments. It operates across global biotech markets, leveraging proprietary cannabinoid-based formulation technologies to advance its pipeline of therapeutic candidates.
Revenue
$2.0M
Gross Profit
$1.5M
Operating Profit
$-3.0M
Net Profit
$-2.9M
Gross Margin
74.2%
Operating Margin
-150.5%
Net Margin
-148.7%
YoY Growth
N/A
EPS
$10.85
SciSparc Ltd. Q2 FY2023 Financial Summary
SciSparc Ltd. reported revenue of $2.0M for Q2 FY2023, with a net profit of $-2.9M (up 49.1% YoY) (-148.7% margin). Cost of goods sold was $508.0K, operating expenses totaled $4.4M.
Key Financial Metrics
| Total Revenue | $2.0M |
|---|---|
| Net Profit | $-2.9M |
| Gross Margin | 74.2% |
| Operating Margin | -150.5% |
| Report Period | Q2 FY2023 |
SciSparc Ltd. Quarterly Revenue & Net Profit History
SciSparc Ltd. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $461.0K | -45.1% | $-9.4M | -2041.6% |
| Q4 FY2024 | $466.0K | — | $-3.8M | -813.9% |
| Q2 FY2024 | $840.0K | -57.4% | $-3.7M | -438.0% |
| Q2 FY2023 | $2.0M | — | $-2.9M | -148.7% |
Income Statement
| Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $2.0M | $840000 | $466000 | $461000 |
| YoY Growth | N/A | -57.4% | N/A | -45.1% |
Balance Sheet
| Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $9.9M | $10.5M | $10.3M | $5.1M |
| Liabilities | $3.1M | $1.8M | $1.4M | $5.2M |
| Equity | $6.8M | $8.7M | $8.9M | $-81000 |
Cash Flow
| Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Operating CF | $-3.2M | $-2.2M | $-2.9M | $-1.9M |